GSK Licenses Halozyme's ENHANZE Drug Delivery Technology
Halozyme Therapeutics, Inc. (HALO) has inked a global collaboration and license agreement with GSK plc (GSK) to develop subcutaneous formulations of multiple promising oncology targets. Under the agreement, GSK has licensed Halozyme's ENHANZE drug …